Global Human Microbiome Modulators Market, By Product (Probiotics and Creams, Prebiotics and Dietary Supplements, Drugs), Application (Digestive Health, Immune Health, Women's Health, Oral Health, Others)– Industry Trends and Forecast to 2029
Human Microbiome Modulators Market Analysis and Size
The market for human microbiome modulators market is expected to grow in the forecast period of 2022-2029. The microbiome modulators are intended to inhibit protein fermentation and the formation of toxic metabolites including NH3, amines, and phenolics while promoting the fermentation of carbohydrates and the production of short chain fatty acids (SCFAs), or good metabolites.
Data Bridge Market Research analyses that the human microbiome modulators market which was USD 115.42 billion in 2021, would rocket up to USD 372.43 billion by 2029, and is expected to undergo a CAGR of 15.77% during the forecast period 2022 to 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Human Microbiome Modulators Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2014 - 2019)
|
|
Quantitative Units
|
Revenue in USD Billion, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Product (Probiotics and Creams, Prebiotics and Dietary Supplements, Drugs), Application (Digestive Health, Immune Health, Women's Health, Oral Health, Others)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Sanofi (France), Procter & Gamble (U.S.), Bayer AG (Germany), DSM (Netherlands), DuPont (U.S.), Yakult Honsha Co., Ltd. (Japan), BioGaia AB (Sweden), Probi (Sweden), Chr. Hansen Holding A/S (Denmark), Ingredion (U.S.), Immuron (Australia), BioGaia (Sweden), ISOThrive Inc. (U.S.), Jarrow Formulas Inc. (U.S.), Lallemand Inc. (Canada)
|
|
Market Opportunities
|
|
Market Definition
The microbiome modulators are intended to inhibit protein fermentation and the formation of toxic metabolites including NH3, amines, and phenolics while promoting the fermentation of carbohydrates and the production of short chain fatty acids (SCFAs), or good metabolites. The SCFAs fuel colonocytes, promote intestinal motility, absorb nutrients, maintain colonic pH, boost the immune system, and have antineoplastic properties.
Human Microbiome Modulators Market Dynamics
Drivers
- Increasing investment for healthcare infrastructure
The significant factor influencing the market growth rate is the rising healthcare expenditure which helps improve its infrastructure. Also, various government organizations aim to improve the healthcare infrastructure by increasing funding, which will further influence the market dynamics.
- Rise in the geriatric population
In the forecast period of 2022–2029, factors such as the rising number of patients with lifestyle-related disorders, the increasing geriatric population worldwide, the increasing demand for preventive medicine, and the lower success rates of treatments for specific diseases, are likely to contribute to the growth of the market for human microbiome modulators.
- Increase in lifestyle diseases
The key factors that promote the growth of the human microbiome market are an increase in industry-institute partnerships, increasing incidence of lifestyle diseases, rising focus on human microbiome therapies, growing technological advancements in metagenomics and next-generation sequencing.
Opportunities
- Government Initiatives
Increasing funding initiatives and government programs to support this research are high impact rendering drivers anticipated to foster the market growth. In 2019, the "Million Microbiome of Humans Project" (MMHP) was launched at the 14th International Conference on Genomics (ICG-14) in China.
- Rise in new applications
On the other hand, rising new applications, a desire for next-generation probiotics, and the availability of funding for the development of cutting-edge technology will all contribute to the expansion of the market for human microbiome modulators over the forecast period.
Restraints/Challenges
- Unfavourable policies
On the other hand, the unfavourable policies of the government on prebiotics and probiotics, insufficient applications based research will obstruct the market's growth rate. The dearth of skilled professionals and lack of healthcare infrastructure in developing economies will challenge the market.
- High cost
High cost, limited infrastructural facilities and inadequate research on the human microbiome are some of the restraining factors of the market.
This human microbiome modulators market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the human microbiome modulators market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
COVID-19 Impact on Human Microbiome Modulators Market
In 2020, the human microbiome modulators may significantly impact the intensity of the illness and susceptibility to the SARS-CoV-2 infection, according to the paper "Lung microbiome and COVID-19: Possible relationship and consequences" published in the Human Microbiome Journal. The findings also revealed that the human microbiome modulators may impact COVID-19 outcomes and is critical for developing immune responses against viral infection. Thus, the rising number of research projects in the microbiome field are the important factors supporting this market.
Recent Developments
- In 2019, The Canadian government announced an expenditure of USD 18 million for microbiome research. With the help of this investment, seven research teams from all around the nation may be able to better understand how the microbiome affects conditions including diabetes, inflammatory bowel disease in children, maternal malnutrition, and cervical cancer. Thus, these research programmes and increasing government financing have made North America one of the key marketplaces for the human microbiome and assisted in its healthy growth.
Global Human Microbiome Modulators Market Scope
The human microbiome modulators market is segmented on the basis of product, application. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Product
- Probiotics and Creams
- Prebiotics and Dietary Supplements
- Drugs
Applications
- Digestive Health
- Immune Health
- Oral Health
- Others
Human Microbiome Modulators Market Regional Analysis/Insights
The human microbiome modulators market is analysed and market size insights and trends are provided by country, product, application as referenced above.
The countries covered in the human microbiome modulators market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America dominates the human microbiome modulators market due to the adoption of advanced technologies.
Asia-Pacific is expected to grow at the highest growth rate in the forecast period of 2022 to 2029 due to the introduction of various solutions and advanced technology.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure growth Installed base and New Technology Penetration
The human microbiome modulators market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for human microbiome modulators market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the human microbiome modulators market. The data is available for historic period 2010-2020.
Competitive Landscape and Human Microbiome Modulators Market Share Analysis
The human microbiome modulators market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to human microbiome modulators market.
Some of the major players operating in the human microbiome modulators market are:
- Sanofi (France)
- Procter & Gamble (U.S.)
- Bayer AG (Germany)
- DSM (Netherlands)
- DuPont (U.S.)
- Yakult Honsha Co., Ltd. (Japan)
- BioGaia AB (Sweden)
- Probi (Sweden)
- Chr. Hansen Holding A/S (Denmark)
- Ingredion (U.S.)
- Immuron (Australia)
- BioGaia (Sweden)
- ISOThrive Inc. (U.S.)
- Jarrow Formulas Inc. (U.S.)
- Lallemand Inc. (Canada)
SKU-